Live feed
Filing
SCHEDULE 13D/A
SCHEDULE 13D/A0000899140-25-000478·Benitec Biopharma Inc.
Schedule 13D ownership disclosure
Benitec Biopharma Inc
Common Stock, par value $0.0001 · CUSIP: 08205P209
Event date: 2025-03-26
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- SUVRETTA CAPITAL MANAGEMENT, LLCReported CIK 0001569064
Shares: 15,623,659 · Class: 49.9%
- Averill Master Fund, Ltd.Reported CIK 0001939329
Shares: 13,922,844 · Class: 44.47%
- Averill Madison Master Fund, Ltd.Reported CIK 0002021243
Shares: 1,700,815 · Class: 5.43%
- Aaron Cowen
Shares: 15,623,659 · Class: 49.9%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000899140-25-000478
- Form type
- SCHEDULE 13D/A
- Filer
- Benitec Biopharma Inc.
- CIK
- CIK 1808898
- Filed
- Mar 28, 2025
- Reporting period
- Mar 26, 2025
- Description
- Schedule 13D beneficial ownership